<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856827</url>
  </required_header>
  <id_info>
    <org_study_id>C6463-101</org_study_id>
    <nct_id>NCT03856827</nct_id>
  </id_info>
  <brief_title>A Study of IW-6463 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of IW-6463 When Administered to Healthy Volunteers as Single Ascending Doses, as Multiple Ascending Doses, and Under Fed Versus Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclerion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclerion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stage 1: To assess the safety and tolerability of single-ascending-dose levels of IW-6463
      tablets when administered orally to healthy subjects

      Stage 2: To assess the safety and tolerability of multiple-ascending-dose levels of IW-6463
      tablets administered orally to healthy subjects

      Stage 3: To assess the safety and tolerability of a single dose of IW-6463 when administered
      to health subjects in fed vs fasted states and explore the effects of food on IW-6463
      pharmacokinetics (PK)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">September 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) in the IW-6463 dose-level cohorts vs the (pooled) placebo group.</measure>
    <time_frame>Up to 9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After multiple ascending doses, number of subjects with TEAEs in the IW-6463 dose-level cohorts vs the (pooled) placebo group.</measure>
    <time_frame>Up to 32 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After a single dose, number of subjects with TEAEs in the fed vs fasted dosing period</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of IW-6463 after single-dose administration under fed vs fasted conditions</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>IW-6463</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-6463</intervention_name>
    <description>IW-6463 Tablet</description>
    <arm_group_label>IW-6463</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching Placebo Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an ambulatory adult between 18 and 64 years old at the screening visit with
             the exception of the elderly cohort, who must be 65 years or older at the screening
             visit.

          -  Subject is in good health and has no clinically significant findings on physical
             examination

          -  Women of reproductive potential must have a negative pregnancy test at the time of
             check-in and must agree to use protocol-specified contraception throughout the
             duration of the study and for 3 months after the final dose of study drug

          -  Men must agree to use protocol-specified contraception and also to not donate sperm
             throughout the study and for 3 months after the final dose of study drug

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Any active or unstable clinically significant medical condition

          -  Use of any prescribed or non-prescribed medication

          -  Other exclusion criteria per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Miller</last_name>
    <phone>857-338-3355</phone>
    <email>PMiller@cyclerion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Lead</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

